Современное состояние проблемы лечения резистентного к радиоактивному йоду дифференицированного рака щитовидной железы и клинический случай длительного успешного лечения сорафенибом

Thyroid cancer is one of the most widespreaded malignant endocrine tumors. Morbidity is constantly increasing in the world and in Russian Federation during last decade [1, 2]. So, in the United States marked annual increase of diagnosed cases of thyroid cancer by 6.4% with increasing of mortality by 0.9% [3]. In Russian Federation marked annual increase of diagnosed cases by 5.4% in 2003–2013. In 2013 in Russian Federation diagnosed 9624 new cases of thyroid cancer with morbidity 93.2 on 100 000 citizens [1]. Differentiated thyroid cancer is more than 90% of all cases of thyroid cancer [4].